| 431 |
Current Problems With Valve-in-Valve Procedures |
Tullio Palmerini |
Apr. 17. 25 |
| 430 |
Ultra-Minimalist TAVR: Novel Strategy for a Quick Procedure and Short Hospital Stay |
James Flaherty |
Apr. 17. 25 |
| 429 |
EARLY-TAVR Trial PI's Thought: TAVR vs. Watchful Waiting |
Philippe Genereux |
Apr. 17. 25 |
| 428 |
RESILIA Tissue - Why It Will Improve the Lifetime Management of All Patients |
Kentaro Hayashida |
Apr. 17. 25 |
| 427 |
Bicuspid TAVR: All the Technical Issues and Data From Asan Medical Center |
Jung-Min Ahn |
Apr. 17. 25 |
| 426 |
Cerebral Embolic Protection in TAVR: PROTECTED-TAVR and BHF-PROTECT-TAVI |
David Joel Cohen |
Apr. 17. 25 |
| 425 |
Why I Chose SAPIEN as No. 1 Valve |
Jung-Hee Lee |
Apr. 17. 25 |
| 424 |
The Right Time to Treat |
Philippe Genereux |
Apr. 17. 25 |
| 423 |
TAVR in the Elderly: Futility Versus Utility |
Tullio Palmerini |
Apr. 17. 25 |
| 422 |
Management of Annular Rupture During TAVR |
Kam Tim Chan |
Apr. 17. 25 |
